Biocon Biologics secures market entry date for ophthalmology drug Yesafili in US Ruchika Sharma15 April 2025 4:18 PM ISTAdditionally, Biocon Biologics secured a settlement agreement in Canada with Bayer and Regeneron Pharma for launch of YESAFILI no later than July 1,...
Biocon Biologics forays into US Ophthalmology market with USFDA nod for Yesafili Ruchika Sharma21 May 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, today announced that the U.S....
Biocon arm gets UK MHRA marketing authorisation for ophthalmic drug Yesafili Ruchika Sharma14 Nov 2023 11:29 AM ISTIt is highly similar to the reference product Eylea (aflibercept).
Biocon Biologics gets European Commission nod for critical eye treatment medicine Yesafili Ruchika Sharma21 Sept 2023 1:30 PM ISTBengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced that the European Commission (EC) has granted marketing authorization in...
Biocon Biologics gets EMA Committee positive opinion for Yesafili Ruchika Sharma25 July 2023 5:30 PM ISTIt is highly similar to the reference product Eylea (aflibercept).
